Dr. Gossage is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
6700 Baum Dr
Suite One
Knoxville, TN 37919Phone+1 865-584-5727Fax+1 865-450-9904
Education & Training
Duke University HospitalFellowship, Allergy and Immunology, 1989 - 1992
Cincinnati Children's Hospital Medical CenterResidency, Pediatrics, 1986 - 1989
University of Tennessee Health Science Center College of MedicineClass of 1986
Certifications & Licensure
TN State Medical License 1997 - 2020
WA State Medical License 2013 - 2018
NC State Medical License 1989 - 2015
Publications & Presentations
PubMed
- 351 citationsBenralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging studyMario Castro, Sally E. Wenzel, Eugene R. Bleecker, Emilio Pizzichini, Piotr Kuna
The Lancet. Respiratory Medicine. 2014-11-01 - 337 citationsEffects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophiliaMichel Laviolette, David Gossage, Gail M. Gauvreau, Richard Leigh, Ron Olivenstein
The Journal of Allergy and Clinical Immunology. 2013-11-01 - 418 citationsMEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function.Roland Kolbeck, Alexander Kozhich, Masamichi Koike, Li Peng, Cecilia Andersson
The Journal of Allergy and Clinical Immunology. 2010-06-01
Grant Support
- Adenosine Deaminase Deficiency: Molecular AnalysisNational Institute Of Allergy And Infectious Diseases1990–1992
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
